Compare EHTH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | BYSI |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4M | 58.4M |
| IPO Year | 2006 | 2016 |
| Metric | EHTH | BYSI |
|---|---|---|
| Price | $1.47 | $1.79 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 491.6K | 14.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,395,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $1.20 | $1.18 |
| 52 Week High | $5.89 | $2.50 |
| Indicator | EHTH | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 61.79 |
| Support Level | $1.43 | $1.73 |
| Resistance Level | $1.58 | $1.83 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.20 | 95.83 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.